Despite improvements in technology and pharmacology, adequate management of postoperative pain in patients undergoing major surgery remains challenging and more than 50% of patients continue to experience moderate to severe pain ([@b1-prm-20-179]--[@b3-prm-20-179]). Although regional analgesia techniques provide intense pain relief, they may result in rare but potentially devastating complications ([@b4-prm-20-179]). Opioid-related side effects may delay recovery and rehabilitation. Recent studies have focused on the concept of 'multimodal analgesia' to achieve optimal analgesia, and to reduce the side effects and the required dose of opioids by combining drugs and methods with different modes of action ([@b5-prm-20-179]).

Pain after surgery has a neuropathic component as well as somatic and visceral characteristics, and agents that are effective in the treatment of neuropathic pain are effective in reducing central sensitization ([@b6-prm-20-179]). Pregabalin is a gamma-aminobutyric acid analogue with anticonvulsant effect. Although the primary indication is neuropathic pain, recent studies have evaluated the efficacy of pregabalin in the treatment of acute postoperative pain ([@b7-prm-20-179],[@b8-prm-20-179]).

Lidocaine is a local anesthetic agent that produces an analgesic effect by modifying response to neurons in the dorsal horn, and an anti-inflammatory effect by inhibiting migration and metabolic activation of leukocytes ([@b8-prm-20-179]). Lidocaine has a positive effect on the return of gastrointestinal motility, which has been attributed to earlier mobilization ([@b9-prm-20-179]--[@b11-prm-20-179]).

The aim of our study was to investigate the effects of preoperative oral pregabalin and perioperative intravenous lidocaine infusion in patients undergoing laparotomy on postoperative morphine consumption, adverse effects, gastrointestinal motility, patient satisfaction, time to mobilization and time to discharge.

METHODS
=======

After the approval of the Central Ethics Committee of Pharmaceutical General Directorate of the Ministry of Health (No: 1713 / Date: September 30, 2010) and patients' written consent, the present prospective, randomized, placebo-controlled and double-blinded study included a total of 80 patients, American Society of Anesthesiology classification I to II, 18 to 65 years of age and undergoing elective laparotomy between November 2010 and April 2011. Patients for whom informed consent was not obtained, had American Society of Anesthesiology scores ≥III, liver or kidney failure, chronic pain, epilepsy or other neurological disease or a history of allergy to one of the study drugs were excluded from the study.

The patients were randomly divided into four groups (n=20 per group). In group C (control-placebo), patients ingested placebo capsules 12 h before the operation and on the morning of the operation, and received saline infusion perioperatively. Group L (lidocaine) patients ingested placebo capsules 12 h before surgery and on the morning of surgery, and received a bolus injection of 1.0 mg/kg lidocaine at induction of anesthesia, then a continuous infusion with a Braun Perfusor infusion pump (B. Braun Melsungen, Germany) at a rate of 2 mg/kg/h during the operation until skin closure. Group P (pregabalin) patients ingested 150 mg pregabalin 12 h before surgery and on the morning of surgery, and received saline infusion perioperatively. Group PL (pregabalin + lidocaine) patients ingested 150 mg pregabalin 12 h before surgery and on the morning of surgery, and received bolus injection of 1.0 mg/kg lidocaine at induction of anesthesia, then a continuous infusion at a rate of 2 mg/kg/h perioperatively until skin closure. Randomization was performed with sealed envelope method before the day of surgery when patients arrived to the ward reception area.

Anesthesia was induced with 5 mg/kg to 7 mg/kg thiopental sodium and 0.1 mg/kg intravenous vecuronium bromide in all patients and was maintained with 1 MAC desflurane and 70% nitrogen dioxide in oxygen. Perioperative heart rate, arterial blood pressure, peripheral oxygen saturation and end-tidal carbon dioxide pressure monitoring were performed and the data were recorded at 30 min intervals. Postoperatively, intravenous morphine was administered until visual analogue scale (VAS) scores were \<30, and intravenous patient-controlled analgesia (PCA) consisting of 1 mg/mL morphine solution with 1.5 mg bolus dose and 8 min lockout interval was started in the recovery room.

Postoperative VAS scores (at rest, with coughing and with movement) were first measured in the postanesthesia care unit (time point 0). The measurements were recorded at 2 h intervals for the first 8 h, 4 h intervals for the second 8 h and continued at 6 h intervals for 48 h. Measurements included mean arterial pressure, heart rate, respiratory rate, PCA consumption, additional analgesic requirement, side effects, time to mobilization, time to first defecation and time to discharge. Patient satisfaction scores using a four-point Likert scale questionnaire (0 = poor, 3 = excellent) were recorded in all patients.

Intraoperatively, measurement of mean arterial pressure and heart rate began following placement of hemodynamic monitors and were measured at 15 min intevals.

Statistical analysis
--------------------

To demonstrate a 30% difference in postoperative morphine requirement, it was estimated that 19 patients per group would be required for α=0.05, β=0.1 (power 90%) with a standard effect size of 1.18. The data obtained were compared statistically using repeated-measures ANOVA and the post hoc Tukey-Kramer test; nonparametric data were evaluated using the Kruskal-Wallis test. P\<0.05 was considered to be statistically significant.

RESULTS
=======

There was no significant difference among groups in terms of the demographic characteristics and the duration of surgery (P\>0.05, [Table 1](#t1-prm-20-179){ref-type="table"}). No statistical difference was found among the groups with respect to perioperative mean arterial pressure (P\>0.05, [Table 2](#t2-prm-20-179){ref-type="table"}). Perioperative heart rate at 15 min, 30 min and 60 min was significantly lower in group P, group L and group PL compared with group C (P\<0.05, [Table 2](#t2-prm-20-179){ref-type="table"}).

No difference was detected among the groups with regard to morphine loading dose in the recovery room (P\>0.05). VAS scores were found to be statistically lower in group P, group L and group PL than in group C between 2 h and 16 h postoperatively (P\<0.05, [Table 3](#t3-prm-20-179){ref-type="table"}).

Total PCA morphine consumption was lower in the first postoperative 4 h interval in group P (mean \[± SD\] 16.9±13.1 mg) and group PL (16.4±17.5 mg) compared with the control group (24.2±16.4 mg) (P\<0.05). Morphine consumption was also significantly lower after the postoperative 34 h interval in group P (53.5±49.1 mg) and group PL (65.9±72.8 mg) compared with the control group (87.1±49.3 mg) (P\<0.05). Compared with group C, morphine consumption was statistically lower in group P only at the 40 h (58.6±53.6 mg versus 93.2±52.9 mg) and 48 h (62.8±55.4 mg versus 99.7±54.7 mg) intervals (P\<0.05).

There was no difference among groups with respect to return of bowel sounds. Time to first defecation and mobilization times were statistically shorter in group L and group PL compared with group C (P\<0.05, [Table 4](#t4-prm-20-179){ref-type="table"}).

There was no significant difference among groups in terms of itching. The incidence of nausea was lower in group L and group PL (two of 18 and five of 15 patients experienced nausea, respectively, P\<0.05). Seven patients in group P and 13 patients in group C had nausea ([Table 5](#t5-prm-20-179){ref-type="table"}).

There was no significant difference among groups in terms of patient satisfaction.

DISCUSSION
==========

In the present study, it was found that preoperative oral pregabalin reduced postoperative VAS scores and morphine requirements, while perioperative intravenous lidocaine infusion had a positive effect on VAS scores, gastrointestinal functions, mobilization time and decreased the incidence of nausea. Pregabalin with or without lidocaine provided superior pain relief in patients undergoing laparatomy.

Postoperative pain may have adverse effects on the respiratory, cardiovascular, endocrine, immune, gastrointestinal and locomotor systems, particularly after major surgical procedures, as well as disrupting patient comfort, increasing morbidity and even mortality ([@b1-prm-20-179]). Postoperative pain has a neuropathic component, which may be perceived as hyperalgesia, hyperesthesia or hypoesthesia as a result of peripheral and central sensitization. The incidence of acute postoperative neuropathic pain has been reported to be 1% to 3% in 2002 ([@b12-prm-20-179]).

Administration of systemic opioid and nonsteroidal anti-inflammatory drugs, or injection of neuraxial or perineural local anesthetic and opioid combinations are the most frequently used methods for postoperative pain treatment. However, these methods are inadequate for many patients. Therefore, anticonvulsant agents such as gabapentin and pregabalin, which are effective in the treatment of chronic neuropathic pain, have been used in the treatment of acute postoperative pain in recent years ([@b2-prm-20-179],[@b13-prm-20-179],[@b14-prm-20-179]).

Doses of gabapentin and pregabalin for treatment of postoperative pain ranged from 300 mg to 1200 mg and 150 mg to 300 mg, respectively ([@b14-prm-20-179],[@b15-prm-20-179]). Pregabalin was chosen for the present study because it is easier to use in acute pain due to its linear pharmacokinetics ([@b16-prm-20-179]). As in our study, it has been observed that gabapentin and pregabalin decreased postoperative opiate requirements ([@b17-prm-20-179],[@b18-prm-20-179]).

In patients undergoing laparoscopic gastrectomy, a single preoperative dose of 150 mg pregabalin decreased VAS values and morphine consumption during the first 24 h postoperatively ([@b19-prm-20-179]). Paech et al ([@b20-prm-20-179]) administered a preoperative dose of pregabalin 100 mg and intraoperative acetaminophen in patients undergoing minor gynecological surgery and reported that postoperative pain scores and the fentanyl consumption were similar to the placebo group. This study was performed in ambulatory patients, and side effects and analgesic requirements were interrogated later by telephone. Early discharge also reduced the use of parenteral analgesics.

Systemic local anesthetics have been used for acute and chronic pain for many years. The preferred intravenous anesthetic is lidocaine because of rapid onset and intermediate duration of action ([@b21-prm-20-179]). Although there are a number of studies concerning the effects of pregabalin and lidocaine on postoperative pain, mobilization, time to discharge and postoperative gastrointestinal system functions, ours is the first study comparing the effects of the combination of two medications with each alone and with placebo. We used two 150 mg doses of pregabalin (12 h and 45 min before surgery). In most studies, pregabalin was administered 1 h to 2 h before surgery as a single dose ([@b22-prm-20-179],[@b23-prm-20-179]). In a study investigating the effects of perioperative infusion of lidocaine on major abdominal surgery ([@b20-prm-20-179]), patients were administered a 1.5 mg/kg loading dose 30 min before surgical incision followed by 1.5 mg/kg/h infusion until the end of the first postoperative hour; the total dose of morphine administered by PCA and the additional morphine requirements were found to be lower than those of control group.

The effect of systemic lidocaine on discharge of patients undergoing colorectal surgery was examined and it was reported that bowel function started earlier with lidocaine and that patients were discharged earlier ([@b11-prm-20-179]). Groudine et al ([@b24-prm-20-179]) found similar results in patients undergoing radical retropubic prostatectomy. In the two studies, infusion of lidocaine continued until the end of the first postoperative hour. We stopped lidocaine infusion after closure of skin incision and found the mean time to defecation was shorter. In the two studies related to the postoperative lidocaine infusion, no analgesic effect could be observed ([@b11-prm-20-179],[@b25-prm-20-179]). It was believed that lidocaine infusion, to be effective, should be given during nociceptive stimulus ([@b26-prm-20-179]). Lidocaine was also found to be as effective as epidural block on postoperative pain, bowel functions and hospital discharge in patients undergoing colonic resection ([@b27-prm-20-179]).

The occurrence and the incidence of side effects is important for the quality of postoperative analgesia. Pregabalin has negligible interaction with other drugs and is well tolerated. Adverse effects such as somnolence, dizziness, confusion, headache, ataxia and weight gain have been reported ([@b28-prm-20-179]--[@b31-prm-20-179]). While many of these side effects are due to chronic use of pregabalin, the most common side effects in postoperative patients are dizziness, somnolence and sedation. We did not detect any statistically significant difference in pruritus. Schulmeyer et al ([@b19-prm-20-179]) reported a significant reduction in nausea, vomiting and the use of antiemetics in patients undergoing laparoscopic gastrectomy with preoperative 150 mg pregabalin. Preoperative pregabalin 150 mg did not increase the incidence of side effects in patients undergoing laparoscopic cholecystectomy. However, Mathiesen et al ([@b30-prm-20-179]) administered pregabalin 300 mg and pregabalin 300 mg plus dexamethasone 8 mg to patients undergoing arthroscopy under spinal anesthesia and found that significantly increased sedation and nausea occurred in the pregabalin only group compared with pregabalin plus dexamethasone group and controls. The antiemetic effect of dexamethasone may contribute to this result. More adverse effects such as drowsiness, blurred vision and difficulty in walking were reported in patients given pregabalin 600 mg ([@b31-prm-20-179]). It has been shown that the higher the dose used, the more analgesic effect as well as the higher incidence of adverse effects are observed. To balance the analgesic effect and side effects, we consider that using two doses of 150 mg may be more appropriate. High-dose lidocaine has been reported to have side effects such as paresthesia, nystagmus, convulsion and arrhythmia; however, we did not observe any of these effects.

CONCLUSION
==========

Preoperative oral pregabalin decreased VAS scores. Intraoperative lidocaine infusion decreased the incidence of nausea and hastened the return of gastrointestinal motility. We conclude that preoperative pregabalin with or without lidocaine reduced morphine requirements and provided superior pain relief compared with placebo in patients undergoing laparatomy.
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###### 

Patient characteristics and duration of surgery

  **Characteristic**         **Groups**                             
  -------------------------- ------------ ------------ ------------ ------------
  Age, years                 53.2±15.7    54.0±23.8    51.1±26.2    51.7±19.1
  Body weight, kg            70.0±16.7    69.7±28.7    72.2±25.5    74±25.2
  Sex, male/female, n/n      10/10        8/12         11/9         8/12
  Duration of surgery, min   101.0±78.0   113.3±93.6   114.1±89.8   99.6±145.6

Data presented as mean ± SD unless otherwise specified. P\>0.05 among groups

###### 

Perioperative mean arterial pressure (mm Hg) and heart rate (beats/min)

  **Time**   **Control**   **Pregabalin**   **Lidocaine**   **Pregabalin + lidocaine**                                                                                                                                                                                                          
  ---------- ------------- ---------------- --------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  0 min      104.3±40.5    92.2±36.2        104.6±31.6      86.3±28.0                                                104.5±28.4                                               91.2±27.0                                                96.2±35.1                                                87.4±33.3
  15 min     103.3±41.3    92.4±27.2        96.0±52.5       84.9±30.6^[\*](#tfn3-prm-20-179){ref-type="table-fn"}^   91.9±28.8                                                86.1±27.4^[\*](#tfn3-prm-20-179){ref-type="table-fn"}^   90.8±42.3                                                81.5±29.9^[\*](#tfn3-prm-20-179){ref-type="table-fn"}^
  30 min     96.5±47.8     92.3±24.2        89.7±35.9       85.4±27.9^[\*](#tfn3-prm-20-179){ref-type="table-fn"}^   87.2±35.0                                                85.7±29.8^[\*](#tfn3-prm-20-179){ref-type="table-fn"}^   92.0±37.4                                                84.1±29.4^[\*](#tfn3-prm-20-179){ref-type="table-fn"}^
  60 min     94.6±31.3     89.6±25.8        89.1±48.1       82.1±26.3                                                91.8±36.2                                                74±21.6                                                  86.1±30.4                                                78.8±24.9
  90 min     87.6±40.2     83.4±15.8        87.5±39.4       80.4±34.9                                                91.1±31.5                                                74.1±9.2                                                 84.7±22.0                                                75.7±27.1
  120 min    85.6±25.4     78.4±25.6        81.7±32.7       74.2±22.7                                                96.7±33.1^[\*](#tfn3-prm-20-179){ref-type="table-fn"}^   73.8±29.2                                                73.2±73.2^[\*](#tfn3-prm-20-179){ref-type="table-fn"}^   71.5±31.7
  150 min    75.2±23.4     72.4±14.2        84.2±36.3       74±12.3                                                  88.0±24.8                                                73.7±31.4                                                77.5±18.9                                                74±45.1

Data presented as mean ± SD.

P\<0.05 versus control

###### 

Postoperative pain rating using visual analogue scale scores (0 mm to 100 mm)

  **Time**   **Control**   **Pregabalin**                                          **Lidocaine**                                            **Pregabalin + lidocaine**
  ---------- ------------- ------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------
  0 h        67.0±8.8      60.9±10.5                                               59.8±10.0                                                59.1±9.7
  2 h        44.2±7.6      35.9±9.7^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^   42.5±9.6^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^    38.8±9.1^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^
  4 h        42.3±8.9      31.9±8.8^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^   34.2±10.0^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^   33.0±7.8^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^
  6 h        39.8±6.5      27.9±5.2^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^   33.3±8.4^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^    28.8±5.8^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^
  8 h        34.0±7.2      24.0±5.3^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^   31.0±8.9^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^    29.1±5.2^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^
  12 h       32.3±6.6      23.4±5.7^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^   29.3±5.2                                                 28.8±6.3^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^
  16 h       29.0±7.0      24.0±5.7^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^   28.2±6.7                                                 26.3±4.2^[\*](#tfn5-prm-20-179){ref-type="table-fn"}^
  22 h       25.0±7.4      23.7±4.9                                                24.7±4.8                                                 25.3±4.5
  28 h       27.2±5.8      24.3±5.7                                                27.1±9.4                                                 23.4±6.5
  34 h       25.4±4.1      25.5±7.0                                                23.9±3.3                                                 22.7±4.6
  40 h       24.8±5.8      24.2±3.0                                                22.6±2.9                                                 22.9±5.0
  48 h       23.1±4.2      22.05±2.9                                               21.25±4.1                                                19.5±5.1

Data presented as mean ± SD.

P\<0.05 versus control

###### 

Time to first bowel sound, defecation, mobilization and discharge, h

  **Variable**   **Control**   **Pregabalin**   **Lidocaine**                                           **Pregabalin + lidocaine**
  -------------- ------------- ---------------- ------------------------------------------------------- -------------------------------------------------------
  Bowel sound    22.9±6.1      22.0±3.5         24.8±3.5                                                24.4±3.6
  Defecation     40.8±10.0     38.6±6.1         32.9±5.5^[\*](#tfn7-prm-20-179){ref-type="table-fn"}^   34.5±5.3^[\*](#tfn7-prm-20-179){ref-type="table-fn"}^
  Mobilization   19.2±3.0      18.3±2.8         17.3±2.4^[\*](#tfn7-prm-20-179){ref-type="table-fn"}^   17.1±2.8^[\*](#tfn7-prm-20-179){ref-type="table-fn"}^
  Discharge      104.4±27.0    98.5±10.6        97.7±12.5                                               92.3±9.7

Data presented as mean ± SD.

P\<0.05 versus control

###### 

Postoperative side effects

  **Side effect**     **Control**   **Pregabalin**   **Lidocaine**                                       **Pregabalin + lidocaine**
  ------------------- ------------- ---------------- --------------------------------------------------- ---------------------------------------------------
  Pruritus (yes/no)   4/16          0/20             1/19                                                1/19
  Nausea (yes/no)     13/7          7/13             2/18[^\*^](#tfn8-prm-20-179){ref-type="table-fn"}   5/15[^\*^](#tfn8-prm-20-179){ref-type="table-fn"}

P\<0.05 between groups
